Overview

Plan Development for Giving Teclistamab in the Outpatient Setting

Status:
NOT_YET_RECRUITING
Trial end date:
2025-09-04
Target enrollment:
Participant gender:
Summary
This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient administration of teclistamab.
Phase:
PHASE4
Details
Lead Sponsor:
University Health Network, Toronto
Collaborator:
Janssen Inc.
Treatments:
tocilizumab